Medivate Partners is a Seoul-based private equity and venture capital firm founded in 2012 that specializes in cross-border life sciences. See contact routes.
Medivate Partners is a Seoul-based private equity and venture capital firm founded in 2012 that specializes in cross-border life sciences investments between Asia and North America. The firm’s investment thesis targets growth-stage biotech and healthcare companies, with a geographic focus on North Asia (particularly Korea) and the United States to arbitrage cross-border opportunities. While specific check sizes and lead/follow behavior are not publicly detailed, the firm has executed notable growth investments, including a $12 million round in SillaJen. Its portfolio includes clinical-stage biotech firms and contract development manufacturing organizations (CDMOs), with SillaJen and WCCT Global cited as key investments. Medivate distinguishes itself by leveraging strategic partnerships with portfolio companies and providing access to top-tier syndicates in the Asia–North America life science corridor. The firm does not appear to publish public writing or a distinctive point of view beyond its operational focus on cross-border value investing in biotech.
Details on this firm come from filing and round data held in the StartupFundraising directory, refreshed on ingest. Founders use profiles like this one to qualify fit and to shortlist comparable investors.
Investors like Medivate Partners · Full investor directory · Investor access · Company funding database